Abstract: The present invention is related to a process of preparing substituted p-aminophenol compound of formula (I) or a salt thereof,

Abstract: Dihydrate and anhydrous crystalline forms of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2?,3?-e] [1,4]diazepin-6-one.

Abstract: This invention provides a method for generating secondary phosphines from secondary phosphine oxides in the presence of a reducing agent, such as diisobutylaluminum hydride (DIBAL-H), triisobutyldialuminoxane, triisobutylaluminum, tetraisobutyldialuminoxane, or another reducing agent comprising: (i) an R1R2AlH moiety, wherein R1 and R2 are each an alkyl species or oxygen, and wherein at least one of R1 or R2 comprises at least 2 carbon atoms, or (ii) an R1R2R3Al moiety, wherein R1, R2, and R3 are not hydrogen, and wherein at least one of R1, R2, and R3 is an alkyl species comprising a ?-hydrogen, not including triethylaluminum. Preferred reducing agents for the present invention include: diisobutylaluminum hydride, triisobutyldialiuminoxane, triisobutylaluminum, tetraisobutyldialuminoxane, and combinations thereof.

Abstract: Disclosed is a process for preparing a macrocyclic compound of the formula (I) wherein a hydroxyl-substituted macrocyclic compound of formula (3) is reacted with a sulfonyl-substituted compound of formula QUIN: The compounds of formula (I) are potent active agents for the treatment of hepatitis C virus (HCV) infection.

Abstract: Disclosed are highly convergent processes for preparing compounds of formula (I), which compounds are potent active agents for the treatment of hepatitis C virus (HCV) infection: The disclosed processes use SNAr-type coupling reactions between peptidic compounds having a hydroxyproline moiety of the following formula: and halogenated or sulfonated bromoquinoline compounds.

Abstract: Dihydrate and anhydrous crystalline forms of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2?,3?-e] [1,4]diazepin-6-one.

Abstract: Disclosed is a multi-step process for preparing a macrocyclic compound of the formula (I): wherein Q is a radical of the following formula: and the other variables are as defined herein. The compounds of formula (I) are potent active agents for the treatment of hepatitis C virus (HCV) infection.

Abstract: This invention provides a method for generating secondary phosphines from secondary phosphine oxides in the presence of a reducing agent, such as diisobutylaluminum hydride (DIBAL-H), triisobutyldialuminoxane, triisobutylaluminum, tetraisobutyldialuminoxane, or another reducing agent comprising: (i) an R1R2AlH moiety, wherein R1 and R2 are each an alkyl species or oxygen, and wherein at least one of R1 or R2 comprises at least 2 carbon atoms, or (ii) an R1R2R3Al moiety, wherein R1, R2, and R3 are not hydrogen, and wherein at least one of R1, R2, and R3 is an alkyl species comprising a ?-hydrogen, not including triethylaluminum. Preferred reducing agents for the present invention include: diisobutylaluminum hydride, triisobutyldialiuminoxane, triisobutylaluminum, tetraisobutyldialuminoxane, and combinations thereof.

Abstract: Disclosed are processes of making dipeptide compounds of formula(I) as further described in the detailed description section:

Abstract: The invention relates to the field of pharmaceutics and more specifically to compositions useful in the preparation of cycloalkyaminoacids and processes for making cycloaminoacids wherein A is a cycloalkyl optionally partially or fully halogenated and optionally substituted with one or more OH, NH2, SO2, phenyl or CF3; X is C0-8.

Abstract: A process and novel intermediates for making compounds of the formula I: wherein: R2 is selected from the group consisting of H, F, Cl, C1-4 alkyl, C3-4 cycloalkyl and CF3; R4 is H or Me; R5 is H, Me or Et, with the proviso that R4 and R5 are not both Me, and if R4 is Me then R5 cannot be Et; R11 is Me, Et, cyclopropyl, propyl, isopropyl, or cyclobutyl; and Q is selected from the group consisting of:

Abstract: A process and novel intermediates for making compounds of the formula I: 1

Abstract: A new class of chiral bidentate ligands to transition metals is disclosed which compounds have the following structure: wherein the substituents are as defined herein.

Abstract: Novel imidazo[2,1-b][3]benzazepines and pyrimido[2,1-b][3]benzazepines of formula I, pharmaceutical compositions containing them, methods for treating cardiac arrhythmia in mammals utilizing them, and processes for synthesizing them.

Abstract: Novel imidazo[1,2-b][2]benzazepines and pyrimido[1,2-b][2]benzazepines of formula I, pharmaceutical compositions containing them, methods for treating cardiac arrhythmias in mammals utilizing them, and processes for synthesizing them.